CSI Market
Sign In | Register

Dyne Therapeutics Inc (DYN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access DYN Annual Cash Flow →
The table below presents a historical view of Dyne Therapeutics Inc's cash flow activity, supporting analysis of liquidity trends over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-299.41
Depreciation & amortization1.11
Amortization of Other Assets0.00
Minority interests0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
Sale of assets0.00
Gain (Loss) on Disposition of Assets, Total-0.03
Share-based Compensation28.06
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Deconsolidation Gain Or Loss Amount-
Tangible Asset Impairment Charges0.12
Income Loss From Equity Method Investments Net Of Dividends Or Distribution Cash Flow Impact-
Gain Loss From Price Risk Management Activity-
Gain Loss From Price Risk Management Activity Affiliates-
Impairment Provisions And Other Charges-
Impairment Loss For Related Party Receivable-
Unrealized Gain Loss On Derivatives Related Parties-
Gains Losses On Sales Of Assets-
Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss Included In Other Income-
Increase Decrease From Affiliate Transactions-
Income taxes0.00
Unrealized Gain (Loss) on Derivatives0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Other Operating Liabilities14.16
Accrued liabilities0.00
Risk-management0.00
Increase (Decrease) in Prepaid Expense and Other Assets23.36
Other Working Capital-4.38
Other Noncash Income (Expense)0.00
Other net1.10
Payments for (Proceeds from) Other Operating Activities-39.18
Discontinued operations0.00
Net Cash flow from Operating Activities-275.21
Investing Activities
Capital Expenditures-1.74
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities43.42
Payments to Acquire Marketable Securities-107.06
Proceeds from other investments0.00
Proceeds From Affiliate Transactions33.46
Increase (Decrease) in Restricted Cash0.00
Noncontrolling interest0.00
Proceeds from Investments0.00
Purchases of Investments0.00
Purchases of non-current assets0.00
Acquisition Net of Cash Acquired0.00
Proceeds from Equity Method Investment, Dividends or Distributions, Return of Capital0.00
Sale of businesses0.00
Proceeds from sale of assets0.00
Notes receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net58.19
Discontinued operations0.00
Net Cash Flow from Investing Activities-7.19
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.03
Long-term debt - borrowings49.45
Long-term debt - repayments0.00
Noncontrolling interest0.00
Issuances / -repurchases of Comm. Stock2.05
Exercise of stock options0.00
Issuances / -repurchases of Pref. Stock0.00
Discontinued Operations0.00
Other financing activities net0.16
Other net13.55
Payments Relatedto Bankruptcy Financing-
Dividends paid to minority interests0.00
Dividends paid0.00
Net Cash Flow from Financing Activities65.17
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-276.94
Total Cash Flow-217.22
4 historic quarters locked

Sign in to unlock the full Dyne Therapeutics Inc cash flow history.

Sign In Create Free Account

About Dyne Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: July 29, 2026
  • Source: dyn-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-323639

Figures are derived from filed reports and may be restated. Historical data is subject to revision.